Showing 1 posts of 1 posts found.
Merrimack Pharmaceuticals has taken the decision to terminate development of its antibody-directed nanotherapeutic cancer therapy MM-310 in the treatment of …
MHRA approves first lower-carbon beclometasone inhalers for asthma
Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide
Novogenia breaks ground on personalised healthcare campus
InfectoPharm launches Polish operations with first hospital antibiotic
FibroFind appoints Lee Borthwick as CEO